The bivariate NRIP1/ZEB2 RNA marker permits non-invasive presymptomatic screening of pre-eclampsia

Vera Manders, Allerdien Visser, Remco Keijser, Naomi Min, Ankie Poutsma, Joyce Mulders, Tarah van den Berkmortel, Marjolein Hortensius, Aldo Jongejan, Eva Pajkrt, Erik A Sistermans, Daoud Sie, Myron G Best, Tom Würdinger, Marjon de Boer, Gijs Afink, Cees Oudejans

Research output: Contribution to journalArticleAcademicpeer-review


Using genome-wide transcriptome analysis by RNA sequencing of first trimester plasma RNA, we tested whether the identification of pregnancies at risk of developing pre-eclampsia with or without preterm birth or growth restriction is possible between weeks 9-14, prior to the appearance of clinical symptoms. We implemented a metaheuristic approach in the self-learning SVM algorithm for differential gene expression analysis of normal pregnancies (n = 108), affected pregnancies (n = 34) and non-pregnant controls (n = 19). Presymptomatic candidate markers for affected pregnancies were validated by RT-qPCR in first trimester samples (n = 34) from an independent cohort. PRKG1 was significantly downregulated in a subset of pregnancies with birth weights below the 10thpercentile as shared symptom. The NRIP1/ZEB2 ratio was found to be upregulated in pregnancies with pre-eclampsia or trisomy 21. Complementary quantitative analysis of both the linear and circular forms of NRIP1 permitted discrimination between pre-eclampsia and trisomy 21. Pre-eclamptic pregnancies showed an increase in linear NRIP1 compared to circular NRIP1, while trisomy 21 pregnancies did not.

Original languageEnglish
Article number21857
Number of pages1
JournalScientific Reports
Issue number1
Publication statusPublished - 14 Dec 2020

Cite this